Higher risk of VTE in CKD surgical patients on enoxaparin

Higher risk of VTE in CKD surgical patients on enoxaparin
For patients with chronic kidney disease who undergo total hip replacement, the rate of major venous thromboembolism is significantly higher in those treated with enoxaparin compared to those treated with desirudin, according to a study published online June 4 in the Journal of Thrombosis and Haemostasis.

(HealthDay) -- For patients with chronic kidney disease (CKD) who undergo total hip replacement (THR), the rate of major venous thromboembolism (VTE) is significantly higher in those treated with enoxaparin compared to those treated with desirudin, according to a study published online June 4 in the Journal of Thrombosis and Haemostasis.

Andrew F. Shorr, M.D., M.P.H., of the Washington Hospital Center in the District of Columbia, and colleagues conducted a post-hoc subgroup analysis of a multicenter, randomized, double-blind study of 577 patients with stage 3B or worse CKD who were treated with desirudin or after elective THR. Thrombosis and bleeding outcomes were assessed for participants who received desirudin, 15 mg twice daily, or enoxaparin, 40 mg/day, administered subcutaneously.

The researchers found that the proportion of patients who experienced a major VTE was significantly higher in the enoxaparin group versus the desirudin group (11.1 versus 3.4 percent; model-adjusted odds ratio, 3.52). The rate of major bleeding did not differ significantly between groups, regardless of patient renal function.

"CKD has been reported previously to increase the risk of bleeding with anticoagulants and these findings suggest that CKD may also increase risk of major VTE for patients treated with enoxaparin, but not for patients treated with desirudin," the authors write. "Clinicians should consider the impact of CKD on risk of VTE when choosing a prophylaxis agent."

Several authors disclosed to Canyon Pharmaceuticals Inc., which funded the study and manufactures desirudin.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Prophylaxis with apixaban feasible for cancer patients

Mar 29, 2012

(HealthDay) -- Primary venous thromboembolism prophylaxis with apixaban, an oral direct Factor Xa inhibitor, in ambulatory cancer patients undergoing first- or second-line chemotherapy for advanced or metastatic ...

Recommended for you

Two expats die of MERS in Saudi commercial hub

8 hours ago

Two foreigners died of MERS in the Saudi city of Jeddah, the health ministry said Saturday, as fears rise over the spreading respiratory virus in the kingdom's commercial hub.

UAE reports 12 new cases of MERS

8 hours ago

Health authorities in the United Arab Emirates have announced 12 new cases of infection by the MERS coronavirus, but insisted the patients would be cured within two weeks.

Filipino tests negative for Middle East virus

20 hours ago

A Filipino nurse who tested positive for the Middle East virus has been found free of infection in a subsequent examination after he returned home, Philippine health officials said Saturday.

User comments